Objectives: To evaluate the clinical effectiveness of canagliflozin 100 mg (cana 100) in type 2 diabetes mellitus (T2DM) patients in an actual practice setting and to determine the effect of Canagliflozin on determinants of adiposity like body weight and body mass index (BMI).

Methods: In this retrospective cohort study, we used the private clinic medical records database. We included individuals with T2DM who were initiated Canagliflozin 100 mg at any time before 24 weeks (± 2 weeks). Changes in HbA1c, fasting plasma glucose (FPG), post-prandial glucose (PPG), body weight, BMI, occurrence of adverse effects/events at 12 and 24 weeks from baseline were evaluated.

Results: We identified 50 individuals with T2DM who were initiated with Cana 100 mg 24weeks (± 2 weeks) prior to collection of data. Individuals were, on average 53.3 ± 6.23 years old and 28% were female. Mean HbA1c, FPG, PPG, SBP, DBP, weight, BMI at baseline were 8.4%, 158.7 mg/dl, 236.5 mg/dl, 124.9 mm Hg, 82.3 mm Hg, 71.1 kg and 27.2 kg/m2 respectively. At 12 weeks, mean HbA1c decreased by 0.9%, PPG reduced by 53.6 mg/dl, weight decreased by 1.4 kg, BMI reduced by 0.5 kg/m2. At 24 weeks, outcomes were improved further: 1.6% reduction in HbA1c, 30.4 mg/dl reduction in FPG, 76.1 mg/dl reduction in PPG, 2.1 kg reduction in weight, 0.8 kg/m2 reduction in BMI. 6 patients reported incidence of genital infections and was treated symptomatically.

Discussion: In clinical trials, Canagliflozin 100 mg has shown efficacy in reducing HbA1c, FPG, PPG, SBP, DBP and body weight. The present study demonstrated efficacy of Cana 100 mg in T2DM patients under real world setting with similar reductions in HbA1c and body weight but slightly higher reductions in FPG and PPG than those shown in clinical trials. The study also showed reductions in determinants of adiposity like body weight and BMI.

Conclusion: The real-world data suggests that Cana 100 mg improved parameters of glycemic control, adiposity and body weight in T2DM patients in line with clinical trial outcomes.

Disclosure

S. Chakravorty: None.

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.